Search
Descriptor English: Alemtuzumab
Descriptor Spanish: Alemtuzumab
Descriptor alemtuzumab
Entry term(s) Campath
Campath 1 G
Campath 1G
Campath 1H
Campath 1M
Campath-1-G
Campath-1G
Campath-1H
Campath-1M
Campath1G
Campath1H
Lemtrada
MabCambath
anticuerpo monoclonal Campath 1H
anticuerpo monoclonal Campath-1H
Scope note: Anticuerpo monoclonal anti ANTÍGENO CD52 utilizado en el tratamiento de ciertos tipos de linfomas CD52 positivos (p. ej., la LEUCEMIA LINFOCÍTICA CRÓNICA, el LINFOMA CUTÁNEO DE LINFOCITOS T y el LINFOMA DE CÉLULAS T). Su mecanismo de acción incluye la CITOTOXICIDAD DEPENDIENTE DE ANTICUERPOS.
Descriptor Portuguese: Alemtuzumab
Descriptor French: Alemtuzumab
Entry term(s): Antibody Campath-1H, Monoclonal
Campath
Campath 1 G
Campath 1G
Campath 1H
Campath 1M
Campath-1-G
Campath-1G
Campath-1H
Campath-1H, Monoclonal Antibody
Campath-1M
Campath1G
Campath1H
Lemtrada
MabCambath
Monoclonal Antibody Campath 1H
Monoclonal Antibody Campath-1H
Tree number(s): D12.776.124.486.485.114.224.060.313
D12.776.124.790.651.114.224.060.375
D12.776.377.715.548.114.224.200.375
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000074323
Scope note: An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g., CHRONIC LYMPHOCYTIC LEUKEMIA; CUTANEOUS T-CELL LYMPHOMA; and T-CELL LYMPHOMA). Its mode of actions include ANTIBODY-DEPENDENT CELL CYTOTOXICITY.
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AN analysis
BI biosynthesis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
DE drug effects
EC economics
GE genetics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PH physiology
PK pharmacokinetics
PO poisoning
RE radiation effects
TO toxicity
TU therapeutic use
UL ultrastructure
UR urine
Pharm Action: Antineoplastic Agents, Immunological
Registry Number: 3A189DH42V
Public MeSH Note: 2018; ALEMTUZUMAB was indexed under ANTIBODIES, MONOCLONAL, 1995-2011 and under ANTIBODIES, MONOCLONAL, HUMANIZED, 2012-2017
History Note: 2018 (1995)
Related: CD52 Antigen MeSH
DeCS ID: 57065
Unique ID: D000074323
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2018/01/01
Date of Entry: 2017/07/11
Revision Date: 2017/04/10
Alemtuzumab - Preferred
Concept UI M0253968
Scope note An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g., CHRONIC LYMPHOCYTIC LEUKEMIA; CUTANEOUS T-CELL LYMPHOMA; and T-CELL LYMPHOMA). Its mode of actions include ANTIBODY-DEPENDENT CELL CYTOTOXICITY.
Preferred term Alemtuzumab
Campath 1H - Narrower
Concept UI M0446621
Preferred term Campath 1H
Entry term(s) Antibody Campath-1H, Monoclonal
Campath-1H
Campath-1H, Monoclonal Antibody
Campath1H
Monoclonal Antibody Campath 1H
Monoclonal Antibody Campath-1H
Campath 1M - Narrower
Concept UI M0282460
Preferred term Campath 1M
Entry term(s) Campath-1M
MabCambath - Narrower
Concept UI M0477047
Preferred term MabCambath
Lemtrada - Narrower
Concept UI M000626122
Preferred term Lemtrada
Campath 1G - Narrower
Concept UI M0237459
Preferred term Campath 1G
Entry term(s) Campath 1 G
Campath-1-G
Campath-1G
Campath1G
Campath - Narrower
Concept UI M0446622
Preferred term Campath



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey